Phase 3 Study KW-0761Versus Vorinostat in CTCL Patients

• Research type

  Research Study

• Full title

  Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

• IRAS ID

  131161

• Contact name

  Sean Whittaker

• Contact email

  sean.whittaker@kcl.ac.uk

• Sponsor organisation

  Kyowa Hakko Kirin Pharma, Inc.

• Eudract number

  2012-004766-17

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  13/LO/1289

• Date of REC Opinion

  6 Nov 2013

• REC opinion

  Further Information Favourable Opinion